包括的代謝パネル検査市場- 世界の産業規模、シェア、動向、機会、予測、分析項目別、疾患別、エンドユース別（ラボ、PoC、PoC）、地域別、競合別、2020-2030年

包括的代謝パネル（CMP）検査の世界市場は、2024年に124億1,000万米ドルと評価され、予測期間中にCAGR 9.62％で拡大し、2030年には215億6,000万米ドルに達すると予測されています。

CMP検査は、血糖値、肝酵素、腎機能、電解質バランスを分析することにより、代謝全般の健康状態を評価するために使用される基本的な診断ツールです。代謝性疾患や慢性疾患の負担が増加していることに加え、予防ヘルスケアと早期診断が世界的に重視されていることが、市場の需要を促進しています。

世界中のヘルスケアシステムで定期的なウェルネス検診の導入が進む中、CMP検査は病院、診断ラボ、外来患者の標準的な診断ワークフローに組み込まれつつあります。さらに、自動検査システムやポイントオブケア機器の技術的進歩により、迅速な納期と幅広いアクセスが可能になり、市場を支えています。高齢化が進み、患者のモニタリングニーズが高まる中、CMP検査に対する需要は、特に慢性疾患管理において増加の一途をたどっています。EHRやAIベースのツールのようなデジタル技術の統合は、結果の解釈を強化し、より個別化されたケアに貢献しています。機器のコストや医療が行き届いていない地域でのアクセスの制限といった障壁はあるもの、継続的なヘルスケアイノベーションと意識の高まりにより、市場の見通しは引き続き堅調です。

主な市場促進要因

慢性疾患および代謝性疾患の有病率の上昇

主な市場課題

高度診断機器の高コスト

主要市場動向

個別化・予防ヘルスケアへのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の包括的代謝パネル検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 分析対象物別（K+、Na+、Cl-、CO2、グルコース、BUN、クレアチニン、Ca++、アルブミン、総タンパク質、ALP、ALT、AST、総ビリルビン）
  • 病気別（腎臓病、肝臓病、糖尿病、その他）
  • 最終用途別（研究室、PoC、PoC（機器））
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の包括的代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の包括的代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の包括的代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の包括的代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの包括的代謝パネル検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Abbott Laboratories
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings Limited
• Sonic Healthcare Limited
• Unipath Specialty Laboratory Limited
• SYNLAB International GmbH
• ARUP Laboratories
• Genoptix, Inc.
• Nova Medical, Inc.
• Mindray Medical International Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Comprehensive Metabolic Panel (CMP) Testing Market was valued at USD 12.41 Billion in 2024 and is projected to reach USD 21.56 Billion by 2030, expanding at a CAGR of 9.62% during the forecast period. CMP testing is a fundamental diagnostic tool used to assess overall metabolic health by analyzing blood glucose, liver enzymes, kidney function, and electrolyte balance. The rising burden of metabolic and chronic diseases, along with the global emphasis on preventive healthcare and early diagnosis, is propelling market demand.

As healthcare systems worldwide increasingly adopt routine wellness screenings, CMP tests are being integrated into standard diagnostic workflows across hospitals, diagnostic labs, and outpatient facilities. The market is further supported by technological advancements in automated laboratory systems and point-of-care devices, enabling faster turnaround and broader accessibility. With the growing aging population and increased patient monitoring needs, demand for CMP testing continues to rise, especially in chronic disease management. Integration of digital technologies like EHRs and AI-based tools is enhancing result interpretation, contributing to more personalized care. Despite barriers such as equipment cost and limited access in underserved areas, the market outlook remains strong due to continuous healthcare innovations and rising awareness.

Key Market Drivers

Rising Prevalence of Chronic and Metabolic Disorders

The increasing global incidence of chronic and metabolic diseases is a major factor driving the demand for comprehensive metabolic panel testing. Noncommunicable diseases (NCDs), including cardiovascular conditions, cancers, chronic respiratory diseases, and diabetes, account for a substantial proportion of global mortality, with metabolic dysfunctions such as hyperglycemia, hypertension, and hyperlipidemia being core risk factors.

CMP tests are critical in detecting these underlying abnormalities by evaluating key biomarkers such as glucose, electrolytes, and liver and kidney function. A global analysis indicates that metabolic syndrome affects between 12.5% and 31.4% of the population, with higher rates in regions like the Eastern Mediterranean and the Americas. As early detection becomes integral to disease prevention and long-term health management, the role of CMP testing is expanding in both clinical and primary care settings, driving market growth.

Key Market Challenges

High Cost of Advanced Diagnostic Equipment

The cost associated with procuring and maintaining advanced laboratory analyzers for CMP testing presents a significant challenge, especially for small and mid-sized healthcare providers. High initial capital requirements, coupled with recurring costs for consumables, reagents, and equipment servicing, can limit market penetration in low-resource settings.

In developing regions, many diagnostic facilities lack the financial capacity to upgrade to modern systems capable of performing high-throughput and precise metabolic panel analysis. This disparity in access contributes to inconsistencies in diagnostic availability, delaying early detection and routine monitoring in underserved areas. Addressing cost-related barriers through affordable technology solutions and policy-level interventions remains vital for equitable market expansion.

Key Market Trends

Shift Toward Personalized and Preventive Healthcare

The market is witnessing a strong trend toward personalized and preventive care, with CMP testing playing an increasingly central role. Healthcare providers are leveraging CMP tests to proactively monitor patients for signs of metabolic imbalance, enabling tailored treatment strategies and early intervention.

This trend is supported by advancements in genomics, digital health tools, and AI-driven diagnostics that allow more nuanced interpretation of test results. Employers and insurance providers are also encouraging preventive health screenings through wellness initiatives, further normalizing CMP testing as part of routine healthcare. As healthcare delivery models evolve to prioritize value-based and predictive care, demand for comprehensive metabolic panel testing is set to grow substantially.

Key Market Players

• Abbott Laboratories
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings Limited
• Sonic Healthcare Limited
• Unipath Specialty Laboratory Limited
• SYNLAB International GmbH
• ARUP Laboratories
• Genoptix, Inc.
• Nova Medical, Inc.
• Mindray Medical International Limited

Report Scope:

In this report, the Global Comprehensive Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Comprehensive Metabolic Panel Testing Market, By Analytes:

• K+
• Na+
• Cl-
• CO2
• Glucose
• BUN
• Creatinine
• Ca++
• Albumin
• Total protein
• ALP
• ALT
• AST
• Total bilirubin

Comprehensive Metabolic Panel Testing Market, By Disease:

• Kidney Disease
• Liver Disease
• Diabetes
• Others

Comprehensive Metabolic Panel Testing Market, By End Use:

• Laboratory
• PoC
• PoC (Instruments)

Comprehensive Metabolic Panel Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Comprehensive Metabolic Panel Testing Market.

Available Customizations:

Global Comprehensive Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Comprehensive Metabolic Panel Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
  • 5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
  • 5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Comprehensive Metabolic Panel Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Analytes
  • 6.2.2. By Disease
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Comprehensive Metabolic Panel Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Analytes
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico Comprehensive Metabolic Panel Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Analytes
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada Comprehensive Metabolic Panel Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Analytes
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End Use

7. Europe Comprehensive Metabolic Panel Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Analytes
  • 7.2.2. By Disease
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Comprehensive Metabolic Panel Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Analytes
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany Comprehensive Metabolic Panel Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Analytes
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Comprehensive Metabolic Panel Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Analytes
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Comprehensive Metabolic Panel Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Analytes
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Comprehensive Metabolic Panel Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Analytes
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End Use

8. Asia-Pacific Comprehensive Metabolic Panel Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Analytes
  • 8.2.2. By Disease
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Comprehensive Metabolic Panel Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Analytes
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Comprehensive Metabolic Panel Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Analytes
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea Comprehensive Metabolic Panel Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Analytes
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan Comprehensive Metabolic Panel Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Analytes
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Comprehensive Metabolic Panel Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Analytes
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End Use

9. South America Comprehensive Metabolic Panel Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Analytes
  • 9.2.2. By Disease
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Comprehensive Metabolic Panel Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Analytes
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Comprehensive Metabolic Panel Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Analytes
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Comprehensive Metabolic Panel Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Analytes
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Comprehensive Metabolic Panel Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Analytes
  • 10.2.2. By Disease
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Comprehensive Metabolic Panel Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Analytes
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Comprehensive Metabolic Panel Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Analytes
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Comprehensive Metabolic Panel Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Analytes
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Quest Diagnostics Incorporated
• 14.3. Laboratory Corporation of America Holdings Limited
• 14.4. Sonic Healthcare Limited
• 14.5. Unipath Specialty Laboratory Limited
• 14.6. SYNLAB International GmbH
• 14.7. ARUP Laboratories
• 14.8. Genoptix, Inc.
• 14.9. Nova Medical, Inc.
• 14.10. Mindray Medical International Limited

15. Strategic Recommendations

16. About Us & Disclaimer